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Abstract 
Combination antimalarial therapy is being ex- 
plored to delay development of resistance to 
falciparum malaria. This report describes an un- 
expected drug-induced hepatitis in a previously 
healthy young woman exposed to 2 doses of 
amodiaquine and artesunate. Use of these com- 
binations should be closely monitored. 
Keywords: antimalarial agents, amodiaquine, artesu- 
nate, adverse events, volunteer, liver function, hepatitis, 
South Africa 
Multidrug-resistant Plasmodium falciparum is a global 
problem (WERNSDORFER & PAYNE, 1991). The use of 
antimalarial drug combinations with independent me- 
chanisms of action is a rational approach to delay the 
onset of drug resistance and safeguard existing drugs 
(WHITE & OLLIARO, 1996). Current field research is 
assessing oral artesunate combined with standard anti- 
malarials, e.g., sulfadoxine-pyrimethamine, amodia- 
quine, for treating acute uncomplicated falciparum 
malaria. Artesunate has a short half-life and produces a 
rapid and substantial reduction of malaria parasites; 
those that remain are then killed by the combinant drug 
acting over a longer time period. To complement the 
field studies, an interactive pharmacokinetic study of 
artesunate and amodiaquine was conducted in normal 
healthy volunteers at the University of Cape Town. We 
report the occurrence of asymptomatic hepatitis in a 
woman during this study. 
This single-dose 3-phase cross-over study was con- 
ducted in 15 volunteers, 10 male and 5 female, aged 
19-42 years. All volunteers received 1 dose of oral 
artesunate (4 mg/kg) on day 0, followed, on day 7, by 
either 1 dose of oral amodiaquine (10 mg/kg) alone or 
combined with a single dose of artesunate (4 mg/kg). 
Subjects were given the alternative regimen on day 28. 
Blood for routine haematology and biochemistry was 
taken on days 0, 6,27 and 48. 
Our subject was a healthy 20-year-old South African 
woman of African-Caucasian descent, with no pre- 
vious significant illnesses. During the study she did not 
take any prescribed or over-the-counter drugs, includ- 
ing paracetamol, and had no reported drug allergies. 
She did not drink alcohol and had no risk factors for 
hepatitis B. Her family history was unremarkable. 
Clinically, there were no abnormal physical signs and 
her baseline blood tests were all normal. She received 
artesunate (day 0), amodiaquine (day 7), followed by 
the combination (day 28). Six days after taking artesu- 
nate alone, her aspartate aminotransferase (AST) and 
total bilirubin were normal but she had a slight increase 
in alanine aminotransferase (ALT) of 31 IU/L (normal 
1-25 IU/L) that was not considered clinically signifi- 
cant (Figure). On day 27, all blood tests were normal. 
On day 48, her transaminases were elevated, rising to 
peak values (AST 236 IU/L, ALT 483 IU/L) on day 
69, decreasing thereafter to normal values over 45 days 
(day 124). Lactic dehydrogenase (LDH) and gamma 
glutamyl transpeptidase (yGT) were also elevated. She 
remained asymptomatic and afebrile throughout her 
illness. She did not develop any physical signs of either 
liver dysfunction or the possible aetiology of her hepati- 
tis: in particular no rash, lymphadenopathy, splenome- 
galy, enlarged tonsils. Pertinent investigations were 
non-contributory and included a normal urea, creati- 
nine, CPK, total white cell, neutrophil, lymphocyte 
and eosinophil counts, and prothrombin time. There 
were no atypical lymphocytes. Serologies for hepatitis 
A, B and C, and autoantibodies [anti-nuclear factor 
@NW, anti-mitochondrial and smooth-muscle anti- 
bodies] were negative. A liver ultrasound on day 72 was 
normal. A liver biopsy was postponed after the first 
improved transaminase results. 
This normal, healthy female volunteer developed an 
asymptomatic rise in liver enzymes following the se- 
quential administration of artesunate and amodiaquine 
which we believe was most probably caused by the 
amodiaquine alone. Other causes of asymptomatic he- 
patitis, e.g., Epstein-Barr virus, cytomegalovirus, toxo- 
plasmosis were considered unlikely in the absence of 
other physical signs, the lack of lymphocytosis, her 
immune competent state (HSU et al., 1995). Further- 
more toxoplasmosis is rare in Cape Town (Liver Unit, 
Universitv of Cane Town. nersonal communication). 
Amodiaquinelinduced -hepatitis during malaria pro- 
phylaxis is well described and may be associated with 
neutropenia (LARREY et al., 1986; NEFTEL et al., 1986; 
WOODTLI et al., 1986; CHARMOT & GOUJON, 1987; 
BERNUAU et al., 1988; RAYMOND et al., 1989). These 
side-effects are thought to be immune mediated but the 
pathogenesis remains unclear (CLARKE et al., 1991). 
Hepatitis has occurred from as early as 3 weeks (ex- 
posure to 3 weekly doses) to as late as 10 months of 
prophylaxis (CHARMOT & GOUJON, 1987). Clinically, 
reported cases have ranged from a mild, transient 
elevation of liver enzymes With few symptoms (LARREY 
et al., 1986; CHARMOT & GOUTON. 1987) to fulminant 
hepatitis with either slow recov&y of fun&ion (LARREY 
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Figure. Liver enzyme profiles of a healthy female volunteer participating in an interactive cross-over pharmacokinetic study of oral 
artesunate and oral amodiaquine. (Normal ranges: aspartate aminotransferase (AST) 7-25 IU/L, alanine aminotransferase (ALT) 
l-25 IU/L, total bilirubin (BRN) 1-17 ymol/L, lactic dehydrogenase (LDH) 175-350 IU/L, gamma glutamyl transpeptidase 
(yGT) O-40 IU/L). 
AS = dose of artesunate taken; AQ = dose of amodiaquine taken; AS + AQ = dose of both drugs taken. 
et al., 1986; NEFTEL et al., 1986), or death (NEFTEL 
et al., 1986; BEFWUAU et al., 1988; RAYMOND et al., 
1989). 
Data on hepatic toxicity and amodiaquine use in 
malaria-endemic areas are few. Amodiaquine appears 
to be safer as treatment rather than as prophylaxis. 
However, we are unable to identify studies examining 
delayed onset hepatitis following treatment, or long- 
itudinal studies of repeated treatments (OLLIARO et al., 
1996). Artesunate has been widely used in South-East 
Asia and China and is well tolerated-there have been 
no reported cases of hepatitis (RIBEIRO & OLLURO, 
1998; PRICE et al., 1999). Although we believe the 
amodiaquine alone was the probable cause of the 
hepatitis in our subject, we cannot exclude the possibi- 
lity of an interaction between artesunate and amodia- 
quine. Close to 200 patients have received this 
combination in studies ongoing at the present time. 
Toxicity data from the field are awaited. 
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